E. T. Abdullin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
E. T. Abdullin has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- N. S. Pokrovskiy
National Medical Research Center of Cardiology named after academician Eugene Chazov, Moscow, Russia
7 shared publications - D. V. Losev
Pirogov City Clinical Hospital № 1
4 shared publications - Denis Nikolaevich Protsenko
Pirogov Russian National Research Medical University
4 shared publications - E. Yu. Kalinin
Pirogov City Clinical Hospital № 1
4 shared publications - Efim Munevich Shifman
Pirogov Russian National Research Medical University
4 shared publications - I. V. Kolerova
Pirogov City Clinical Hospital № 1
4 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3) , 67-71
History and current trends in extracorporeal methods of therapy in rheumatology. Part 1. Treatment of systemic lupus erythematosus
История и современные тенденции экстракорпоральных методов терапии в ревматологии. Часть 1. Лечение системной красной волчанки
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3) , 67-71
Open AccessHistory and current trends in extracorporeal methods of therapy in rheumatology. Part 1. Treatment of systemic lupus erythematosus
История и современные тенденции экстракорпоральных методов терапии в ревматологии. Часть 1. Лечение системной красной волчанки
- 30 January 2026
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (4)
The Role of Extracellular DNA Among Predictors of Hospital Mortality in Patients with Septic Shock
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.
- 30 January 2026
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (4)
The Role of Extracellular DNA Among Predictors of Hospital Mortality in Patients with Septic Shock
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.
- Open Access
- 29 December 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 22 (6) , 67-79
Evaluation of the efficacy of extracorporeal blood purification in abdominal septic shock: a prospective interventional controlled study
Introduction. The choice of extracorporeal blood purification (EBP) tactics for septic shock (SS) complicated by acute kidney injury (AKI) remains an unresolved clinical problem. The objective was to evaluate the effectiveness of various EBP approaches in SS management. Materials and methods. Three groups were included in the study: group 1 (n = 34) received conservative therapy and hemodiafiltration (CVVHDF) for urgent indications; group 2 (n = 35) received early isolated CVVHDF; group 3 (n = 32) received early combined EBP (selective plasmapheresis with CVVHDF). We conducted a comparative analysis of clinical and laboratory parameters. Results. Application of early combined EBP as part of intensive therapy by day 3 provided a significantly better stabilization of mean arterial pressure – in 37.7% of cases (p = 0.001) – compared to isolated EBP in the early (18.3%, p = 0.042) and delayed periods (12.8%, p = 0.016); reduced organ dysfunction severity (p = 0.002) compared to day 5 outcomes with early isolated EBP (p = 0.021). ICU and hospital stays were 10.5 (6.7; 15) and 21 (18; 25) days respectively, versus 15 (9.5; 20) and 24 (17.5; 27.5) days for early isolated EBP (p = 0.054 and p = 0.267), and 21 (13.2; 26) and 27.5 (22; 41) days for delayed EBP (p = 0.001 for both). Mortality was 28.1% in the combined group versus 42.9% for early isolated EBP (p = 0.112) and 58.7% for delayed EBP (p = 0.012). Conclusions. Combined EBP as part of intensive therapy enables faster hemodynamic stabilization, improves patients’ clinical status, and leads to better disease outcomes.
- 29 December 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 22 (6) , 67-79
Open AccessEvaluation of the efficacy of extracorporeal blood purification in abdominal septic shock: a prospective interventional controlled study
Introduction. The choice of extracorporeal blood purification (EBP) tactics for septic shock (SS) complicated by acute kidney injury (AKI) remains an unresolved clinical problem. The objective was to evaluate the effectiveness of various EBP approaches in SS management. Materials and methods. Three groups were included in the study: group 1 (n = 34) received conservative therapy and hemodiafiltration (CVVHDF) for urgent indications; group 2 (n = 35) received early isolated CVVHDF; group 3 (n = 32) received early combined EBP (selective plasmapheresis with CVVHDF). We conducted a comparative analysis of clinical and laboratory parameters. Results. Application of early combined EBP as part of intensive therapy by day 3 provided a significantly better stabilization of mean arterial pressure – in 37.7% of cases (p = 0.001) – compared to isolated EBP in the early (18.3%, p = 0.042) and delayed periods (12.8%, p = 0.016); reduced organ dysfunction severity (p = 0.002) compared to day 5 outcomes with early isolated EBP (p = 0.021). ICU and hospital stays were 10.5 (6.7; 15) and 21 (18; 25) days respectively, versus 15 (9.5; 20) and 24 (17.5; 27.5) days for early isolated EBP (p = 0.054 and p = 0.267), and 21 (13.2; 26) and 27.5 (22; 41) days for delayed EBP (p = 0.001 for both). Mortality was 28.1% in the combined group versus 42.9% for early isolated EBP (p = 0.112) and 58.7% for delayed EBP (p = 0.012). Conclusions. Combined EBP as part of intensive therapy enables faster hemodynamic stabilization, improves patients’ clinical status, and leads to better disease outcomes.
- Open Access
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 98-105
Selective plasmosorption of extracellular DNA and NETs in patients with difficult-to-treat rheumatoid arthritis (first clinical experience)
Rheumatoid arthritis (RA) associated with interstitial lung disease (RA-ILD) represents a distinct clinical and pathogenetic phenotype characterized by high inflammatory activity, seropositivity, and systemic manifestations. In recent years, increasing attention has been directed to the role of extracellular DNA and neutrophil extracellular traps (NETs) in RA pathogenesis. This report presents the first case of selective plasmosorption of extracellular DNA and NETs in a patient with RA-ILD. The therapy was associated with a decrease in joint pain and stiffness and improvement of general condition. Laboratory parameters were also monitored dynamically. This clinical case demonstrates the potential of DNA-containing structure plasmosorption as an adjunctive method to enhance the effect of therapy with biological disease modifying antirheumatic drugs in refractory RA.
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 98-105
Open AccessSelective plasmosorption of extracellular DNA and NETs in patients with difficult-to-treat rheumatoid arthritis (first clinical experience)
Rheumatoid arthritis (RA) associated with interstitial lung disease (RA-ILD) represents a distinct clinical and pathogenetic phenotype characterized by high inflammatory activity, seropositivity, and systemic manifestations. In recent years, increasing attention has been directed to the role of extracellular DNA and neutrophil extracellular traps (NETs) in RA pathogenesis. This report presents the first case of selective plasmosorption of extracellular DNA and NETs in a patient with RA-ILD. The therapy was associated with a decrease in joint pain and stiffness and improvement of general condition. Laboratory parameters were also monitored dynamically. This clinical case demonstrates the potential of DNA-containing structure plasmosorption as an adjunctive method to enhance the effect of therapy with biological disease modifying antirheumatic drugs in refractory RA.
- Open Access
- 11 August 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 22 (4) , 17-30
The role of extracorporeal blood purification in correcting intoxication markers in septic shock: a prospective interventional controlled study
Introduction. The use of extracorporeal blood purification (EBP) in septic shock (SS) complicated by acute kidney injury (AKI) remains a con troversial topic.The objective was to evaluate the effectiveness of EBP methods in patients with abdominal SS complicated by AKI.Materials and methods. Group 1 included 34 patients who received continuous veno-venous hemodiafiltration (CVVHDF) as emergency therapy. Group 2 consisted of 35 patients who underwent early isolated CVVHDF. Group 3 comprised 32 patients who received early combined EBP (selec tive plasma filtration + CVVHDF).Results. Combined EBP from day 1 to day 5 of therapy demonstrated a reduction in C-reactive protein from 223.5 to 140.9 mg/L (p = 0.001; −37.1%) compared to group 2 (219.7 to 179.2 mg/L; p = 0.004; −18.4%) and group 1 (214.5 to 189.3 mg/L; p = 0.772; −11.7%), as well as a decrease in interleukin-6 from 242.8 to 70.3 pg/mL (p = 0.001; −71.1%) vs. group 2 (233.7 to 123.4 pg/mL; p = 0.003; −47.2%) and group 1 (247.4 to 184.3 pg/mL; p = 0.512; −25.5%). Tumor necrosis factor levels decreased from 20.1 to 4.6 pg/mL (p = 0.001; −77.1%) in group 3, while group 2 showed a reduction from 19.4 to 11.9 pg/mL (p = 0.001; −38.7%) and group 1 exhibited minimal change (21.4 to 20.5 pg/mL; p = 0.525; −4.2%). Cystatin-C levels in group 3 decreased from 1.45 to 0.85 µg/mL (p = 0.048; −41.4%), whereas group 2 showed a slight reduction (1.6 to 1.5 µg/mL; p = 0.997; −6.3%) and group 1 demonstrated an increase (1.5 to 1.9 µg/mL; p = 0.027; +22.7%).Conclusions. Combined EBP significantly reduces inflammatory markers and improves kidney function compared to isolated renal replacement therapy, both in the early and delayed periods.
- 11 August 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 22 (4) , 17-30
Open AccessThe role of extracorporeal blood purification in correcting intoxication markers in septic shock: a prospective interventional controlled study
Introduction. The use of extracorporeal blood purification (EBP) in septic shock (SS) complicated by acute kidney injury (AKI) remains a con troversial topic.The objective was to evaluate the effectiveness of EBP methods in patients with abdominal SS complicated by AKI.Materials and methods. Group 1 included 34 patients who received continuous veno-venous hemodiafiltration (CVVHDF) as emergency therapy. Group 2 consisted of 35 patients who underwent early isolated CVVHDF. Group 3 comprised 32 patients who received early combined EBP (selec tive plasma filtration + CVVHDF).Results. Combined EBP from day 1 to day 5 of therapy demonstrated a reduction in C-reactive protein from 223.5 to 140.9 mg/L (p = 0.001; −37.1%) compared to group 2 (219.7 to 179.2 mg/L; p = 0.004; −18.4%) and group 1 (214.5 to 189.3 mg/L; p = 0.772; −11.7%), as well as a decrease in interleukin-6 from 242.8 to 70.3 pg/mL (p = 0.001; −71.1%) vs. group 2 (233.7 to 123.4 pg/mL; p = 0.003; −47.2%) and group 1 (247.4 to 184.3 pg/mL; p = 0.512; −25.5%). Tumor necrosis factor levels decreased from 20.1 to 4.6 pg/mL (p = 0.001; −77.1%) in group 3, while group 2 showed a reduction from 19.4 to 11.9 pg/mL (p = 0.001; −38.7%) and group 1 exhibited minimal change (21.4 to 20.5 pg/mL; p = 0.525; −4.2%). Cystatin-C levels in group 3 decreased from 1.45 to 0.85 µg/mL (p = 0.048; −41.4%), whereas group 2 showed a slight reduction (1.6 to 1.5 µg/mL; p = 0.997; −6.3%) and group 1 demonstrated an increase (1.5 to 1.9 µg/mL; p = 0.027; +22.7%).Conclusions. Combined EBP significantly reduces inflammatory markers and improves kidney function compared to isolated renal replacement therapy, both in the early and delayed periods.
- 8 August 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 4
Experience with selective plasmosorption of cfDNA/NETs in a patient with severe acute pancreatitis (case report)
Background. Modality, timing and duration of extracorporeal detoxification (ECD) in patients with severe acute pancreatitis are a controversial and unsolved problem. Objective. To evaluate safety, clinical and laboratory effectiveness of selective plasmosorption (SP) in a patient with severe acute pancreatitis. Material and methods. A 34-year-old patient presented with severe acute pancreatitis complicated by enzymatic shock. Clinical, laboratory and instrumental diagnostic methods were performed. Cell-free deoxyribonucleic acid (cfDNA) SP was used together with standard intensive therapy. The main laboratory parameters were compared. Results. SP significantly reduced the markers of systemic endogenous intoxication: CRP from 64.3 to 29.5 mg/l (54.12%) by the 4th day; leukocytes from 16.2 to 7.8∙109/l (51.85%); IL-1 from 224.1 to 16.7 pg/ml (92.55%); IL-6 from 423.4 to 84.4 pg/ml (80.1%); TNF-α from 627.2 to 102.6 pg/ml (83.64%); cfDNA from 2270 to 10 ng/ml (99.56%), band neutrophils from 18% to 11% (33.89%) by the 7th day. Acid-base state normalized by the 3rd day (pH from 7.15 to 7.31, BE from –11.2 to –2.6, lactate from 4.9 to 1.4 mmol/l). SOFA scores decreased from 6 to 1 point by the 7th day. Conclusion. SP of cfDNA quickly normalizes the main clinical and laboratory parameters, as well as markers of systemic endogenous intoxication.
- 8 August 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 4
Experience with selective plasmosorption of cfDNA/NETs in a patient with severe acute pancreatitis (case report)
Background. Modality, timing and duration of extracorporeal detoxification (ECD) in patients with severe acute pancreatitis are a controversial and unsolved problem. Objective. To evaluate safety, clinical and laboratory effectiveness of selective plasmosorption (SP) in a patient with severe acute pancreatitis. Material and methods. A 34-year-old patient presented with severe acute pancreatitis complicated by enzymatic shock. Clinical, laboratory and instrumental diagnostic methods were performed. Cell-free deoxyribonucleic acid (cfDNA) SP was used together with standard intensive therapy. The main laboratory parameters were compared. Results. SP significantly reduced the markers of systemic endogenous intoxication: CRP from 64.3 to 29.5 mg/l (54.12%) by the 4th day; leukocytes from 16.2 to 7.8∙109/l (51.85%); IL-1 from 224.1 to 16.7 pg/ml (92.55%); IL-6 from 423.4 to 84.4 pg/ml (80.1%); TNF-α from 627.2 to 102.6 pg/ml (83.64%); cfDNA from 2270 to 10 ng/ml (99.56%), band neutrophils from 18% to 11% (33.89%) by the 7th day. Acid-base state normalized by the 3rd day (pH from 7.15 to 7.31, BE from –11.2 to –2.6, lactate from 4.9 to 1.4 mmol/l). SOFA scores decreased from 6 to 1 point by the 7th day. Conclusion. SP of cfDNA quickly normalizes the main clinical and laboratory parameters, as well as markers of systemic endogenous intoxication.
- Open Access
- 30 April 2025
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 2,p. 58-73
Selective plasmofiltration in the treatment of patients with abdominal septic shock: a prospective interventional controlled study
INTRODUCTION: The choice of tactics for the use of extracorporeal detoxification in the form of indications and modality of procedures in patients with abdominal septic shock (SS) remains an unsolved problem. OBJECTIVES: To evaluate the effect of selective plasmofiltration (SPF) as part of complex intensive therapy on the dynamics of markers of systemic inflammatory response syndrome, the severity of the condition and disease outcomes in patients with abdominal SS. MATERIALS AND METHODS: The study included 85 patients with the clinical picture of abdominal SS complicated by acute kidney injury. Group 1 (23 patients) received combined detoxification: SPF and continuous renal replacement therapy (CVVHDF). Group 2 (62 patients) received isolated CVVHDF. A comparative analysis of the main clinical and laboratory parameters and treatment outcomes was performed between the groups. RESULTS: The use of combined detoxification made it possible to reduce markers of systemic endogenous intoxication: C-reactive protein from 225.4 (211; 248.4) to 210.5 (180.39; 230.18) mg/l by the 3rd day of therapy (6.6 %; p = 0.0016), by the 5th–7th–10th days 156.17 (110.67; 180.62), 87 (74.5; 94.1), 62.2 (45.7; 71), respectively (30.7–61.4–72.4 %; p = 0.044; p = 0.0001; p = 0.0001); interleukin-6 demonstrated a decrease of 12.2 % by the 2nd day (p = 0.017) and 35.5, 39.4, 45.7 and 52.4 % by the 3rd–5th–7th–10th days of therapy, respectively (p = 0.022; p = 0.009; p = 0.0018; p = 0.0001); leukocytes from 19.7 (17.7; 22.4) to 17.25 × 109/l (14.65; 19.15) by the 3rd day (12.4 %; p = 0.00045), and 10.9 (9.3; 14.1) by the 10th day (44.7 %; p = 0.00048). Severity of organ dysfunction (SOFA) from 6 (4; 6) on the 1st day to 4 (3; 5) points by the 3rd day of therapy (p = 0.026). A significant difference in survival was obtained (p = 0.037). CONCLUSIONS: Combined detoxification consisting of SPF and CVVHDF allows for rapid normalization of laboratory markers of systemic inflammatory response syndrome and improves patient survival.
- 30 April 2025
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 2,p. 58-73
Open AccessSelective plasmofiltration in the treatment of patients with abdominal septic shock: a prospective interventional controlled study
INTRODUCTION: The choice of tactics for the use of extracorporeal detoxification in the form of indications and modality of procedures in patients with abdominal septic shock (SS) remains an unsolved problem. OBJECTIVES: To evaluate the effect of selective plasmofiltration (SPF) as part of complex intensive therapy on the dynamics of markers of systemic inflammatory response syndrome, the severity of the condition and disease outcomes in patients with abdominal SS. MATERIALS AND METHODS: The study included 85 patients with the clinical picture of abdominal SS complicated by acute kidney injury. Group 1 (23 patients) received combined detoxification: SPF and continuous renal replacement therapy (CVVHDF). Group 2 (62 patients) received isolated CVVHDF. A comparative analysis of the main clinical and laboratory parameters and treatment outcomes was performed between the groups. RESULTS: The use of combined detoxification made it possible to reduce markers of systemic endogenous intoxication: C-reactive protein from 225.4 (211; 248.4) to 210.5 (180.39; 230.18) mg/l by the 3rd day of therapy (6.6 %; p = 0.0016), by the 5th–7th–10th days 156.17 (110.67; 180.62), 87 (74.5; 94.1), 62.2 (45.7; 71), respectively (30.7–61.4–72.4 %; p = 0.044; p = 0.0001; p = 0.0001); interleukin-6 demonstrated a decrease of 12.2 % by the 2nd day (p = 0.017) and 35.5, 39.4, 45.7 and 52.4 % by the 3rd–5th–7th–10th days of therapy, respectively (p = 0.022; p = 0.009; p = 0.0018; p = 0.0001); leukocytes from 19.7 (17.7; 22.4) to 17.25 × 109/l (14.65; 19.15) by the 3rd day (12.4 %; p = 0.00045), and 10.9 (9.3; 14.1) by the 10th day (44.7 %; p = 0.00048). Severity of organ dysfunction (SOFA) from 6 (4; 6) on the 1st day to 4 (3; 5) points by the 3rd day of therapy (p = 0.026). A significant difference in survival was obtained (p = 0.037). CONCLUSIONS: Combined detoxification consisting of SPF and CVVHDF allows for rapid normalization of laboratory markers of systemic inflammatory response syndrome and improves patient survival.
- Open Access
- 31 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (8) , 5957
Association of cell-free DNA with the length of ulcerated plaque in the infarct-related artery and the myocardial infarct size among patients with ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
Aim. To evaluate the changes of cell-free DNA (cfDNA) levels before and after percutaneous coronary intervention (PCI) in patients with ST-segment elevation acute coronary syndrome (STE-ACS). To identify associations of cfDNA concentration before and after PCI with complications and length of ulcerated plaque in patients with STE-ACS.Material and methods. This prospective single-center observational pilot study included 44 patients with STE-ACS admitted to the cardiac intensive care unit during the period of May-August 2023. In all patients, along with standard laboratory tests, cfDNA level was measured upon admission and 24 hours after PCI. Assessment of cfDNA associations before and after PCI was carried out in relation to following significant complications and conditions in STE-ACS patients: death, acute left ventricular failure (ALVF), acute heart failure (AHF), arrhythmia, number of stents implanted, number of segments with impaired local contractility, total stent length.Results. The mean age of the patients was 60,6±9,6 years, of which 74,6% were men. TIMI 0-1 flow was recorded in 93,2% of the subjects. The most common complications were cardiogenic shock (18,4%), arrhythmia (16,9%), AHF (13,6%), ALV (11,9%). Death was recorded in 8,5%. Implantation of 1 stent in PCI was performed in 75% of cases, while in the rest, 2 or more stents were implanted. The proportion of patients with impaired local contractility was 90%, the median stent length was 24,0 (20,0-50,0) mm. CfDNA level on admission did not differ from level after PCI 94,5 (78,3-155,5) ng/ml vs 115,0 (71,0-152,0), p=0,46. However, it significantly exceeded the cfDNA concentration from a group of healthy volunteers (78,0 (59,7-106,0), p=0,017). Characteristic curve showed significant relationships both for the concentration of cfDNA before (with implantation of 2 or more stents (AUC 0,71 with 95% confidence interval (CI) 0,56-0,86, p=0,039), stent length >24 mm (AUC 0,73 with 95% CI 0,58-0,89, p=0,009)) and after PCI (with the number of impaired local contractility segments (AUC 0,73 with 95% CI 0,57-0,89, p=0,014)). If the cfDNA level before PCI was >90 ng/ml, the risk of implantation of 2 or more stents per procedure increased by 5,4 times (odds ratio (OR) 5,4, 95% CI 1,11-28,93, p=0,044). The risk of a stent length >24 mm with pre-PCI cfDNA >107 ng/ml increased 9-fold (OR 9,0 with 95% CI 2,2-36,9, p=0,001), and the cfDNA level after PCI >105 ng/ml increased the risk of impaired local left ventricular (LV) contractility in 2 or more segments by 5 times (OR 5,0, 95% CI 1,23-20,3).Conclusion. In the studied group of patients with STE-ACS subject to intervention, the cfDNA concentration before PCI was associated with the implantation of ≥2 stents and the stent length (>24 mm). CfDNA level before PCI was associated with the number of segments of impaired local LV contractility (≥2).
- 31 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (8) , 5957
Open AccessAssociation of cell-free DNA with the length of ulcerated plaque in the infarct-related artery and the myocardial infarct size among patients with ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
Aim. To evaluate the changes of cell-free DNA (cfDNA) levels before and after percutaneous coronary intervention (PCI) in patients with ST-segment elevation acute coronary syndrome (STE-ACS). To identify associations of cfDNA concentration before and after PCI with complications and length of ulcerated plaque in patients with STE-ACS.Material and methods. This prospective single-center observational pilot study included 44 patients with STE-ACS admitted to the cardiac intensive care unit during the period of May-August 2023. In all patients, along with standard laboratory tests, cfDNA level was measured upon admission and 24 hours after PCI. Assessment of cfDNA associations before and after PCI was carried out in relation to following significant complications and conditions in STE-ACS patients: death, acute left ventricular failure (ALVF), acute heart failure (AHF), arrhythmia, number of stents implanted, number of segments with impaired local contractility, total stent length.Results. The mean age of the patients was 60,6±9,6 years, of which 74,6% were men. TIMI 0-1 flow was recorded in 93,2% of the subjects. The most common complications were cardiogenic shock (18,4%), arrhythmia (16,9%), AHF (13,6%), ALV (11,9%). Death was recorded in 8,5%. Implantation of 1 stent in PCI was performed in 75% of cases, while in the rest, 2 or more stents were implanted. The proportion of patients with impaired local contractility was 90%, the median stent length was 24,0 (20,0-50,0) mm. CfDNA level on admission did not differ from level after PCI 94,5 (78,3-155,5) ng/ml vs 115,0 (71,0-152,0), p=0,46. However, it significantly exceeded the cfDNA concentration from a group of healthy volunteers (78,0 (59,7-106,0), p=0,017). Characteristic curve showed significant relationships both for the concentration of cfDNA before (with implantation of 2 or more stents (AUC 0,71 with 95% confidence interval (CI) 0,56-0,86, p=0,039), stent length >24 mm (AUC 0,73 with 95% CI 0,58-0,89, p=0,009)) and after PCI (with the number of impaired local contractility segments (AUC 0,73 with 95% CI 0,57-0,89, p=0,014)). If the cfDNA level before PCI was >90 ng/ml, the risk of implantation of 2 or more stents per procedure increased by 5,4 times (odds ratio (OR) 5,4, 95% CI 1,11-28,93, p=0,044). The risk of a stent length >24 mm with pre-PCI cfDNA >107 ng/ml increased 9-fold (OR 9,0 with 95% CI 2,2-36,9, p=0,001), and the cfDNA level after PCI >105 ng/ml increased the risk of impaired local left ventricular (LV) contractility in 2 or more segments by 5 times (OR 5,0, 95% CI 1,23-20,3).Conclusion. In the studied group of patients with STE-ACS subject to intervention, the cfDNA concentration before PCI was associated with the implantation of ≥2 stents and the stent length (>24 mm). CfDNA level before PCI was associated with the number of segments of impaired local LV contractility (≥2).
- Open Access
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 75-80
The first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by the overproduction of autoantibodies against various components of the nucleus of the patient's own cells with the development of immunoinflammatory tissue damage. In recent years, more and more data have accumulated on the involvement of neutrophils in the development of the clinical symptoms of SLE, and DNA-containing structures and neutrophil extracellular traps (NETs) playing an important role in this process. Effective neutralization of NETs in SLE can be achieved by removing circulating proteins and molecules associated with NETs from the bloodstream by selective plasma sorption of DNA using the NucleoCapture Device.This article describes the case of a patient who underwent three plasma sorption sessions aiming to suppress the activity of SLE. During the therapy, significant positive dynamics were achieved: the SLEDAI-2K index decreased from 32 to 12 points, the number of leukocytes in the blood normalized, renal function improved, and the immunological activity of the disease decreased.
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 75-80
Open AccessThe first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by the overproduction of autoantibodies against various components of the nucleus of the patient's own cells with the development of immunoinflammatory tissue damage. In recent years, more and more data have accumulated on the involvement of neutrophils in the development of the clinical symptoms of SLE, and DNA-containing structures and neutrophil extracellular traps (NETs) playing an important role in this process. Effective neutralization of NETs in SLE can be achieved by removing circulating proteins and molecules associated with NETs from the bloodstream by selective plasma sorption of DNA using the NucleoCapture Device.This article describes the case of a patient who underwent three plasma sorption sessions aiming to suppress the activity of SLE. During the therapy, significant positive dynamics were achieved: the SLEDAI-2K index decreased from 32 to 12 points, the number of leukocytes in the blood normalized, renal function improved, and the immunological activity of the disease decreased.